UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RET Proto-Oncogene in the Development of Human Cancer

Journal of clinical oncology, 1999-01, Vol.17 (1), p.380-393

ENG, C

1999

Volltextzugriff (PDF)

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4003-4003

2007

Volltextzugriff (PDF)

Papillary and Follicular Thyroid Carcinomas Show Distinctly Different Microarray Expression Profiles and Can Be Distinguished by a Minimum of Five Genes

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3531-3539

2004

Volltextzugriff (PDF)

Prognostic impact of baseline CEA level and surgery of primary tumor among patients with stage IV denovo colon cancer

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.503-503

2011

Volltextzugriff (PDF)

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.527-527

2011

Volltextzugriff (PDF)

Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.551-551

2011

Volltextzugriff (PDF)

Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3529-3529

2011

Volltextzugriff (PDF)

Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS197-TPS197

2010

Volltextzugriff (PDF)

Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3553-3553

2011

Volltextzugriff (PDF)

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3533-3533

2011

Volltextzugriff (PDF)

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3582-3582

2011

Volltextzugriff (PDF)

Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3618-3618

2011

Volltextzugriff (PDF)

Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.539-539

2011

Volltextzugriff (PDF)

A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.366-366

2011

Volltextzugriff (PDF)

Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM)

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.507-507

2011

Volltextzugriff (PDF)

Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.401-401

2011

Volltextzugriff (PDF)

Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.482-482

2011

Volltextzugriff (PDF)

CHFR methylation as an epigenetic marker for recurrence of colon cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4043-4043

2009

Volltextzugriff (PDF)

Association of PTEN loss and local recurrence in stage II-III colon cancer

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.399-399

2011

Volltextzugriff (PDF)

Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): A matched-pair analysis

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e14036-e14036

2011

Volltextzugriff (PDF)

Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3545-3545

2011

Volltextzugriff (PDF)

Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13519-e13519

2010

Volltextzugriff (PDF)

Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3536-3536

2010

Volltextzugriff (PDF)

Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3593-3593

2010

Volltextzugriff (PDF)

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3500-3500

2011

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(132)

Publikationsform

Artikel
(138)

Sprache

Englisch
(138)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

RET Proto-Oncogene in the Development of Human Cancer

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Papillary and Follicular Thyroid Carcinomas Show Distinctly Different Microarray Expression Profiles and Can Be Distinguished by a Minimum of Five Genes

Prognostic impact of baseline CEA level and surgery of primary tumor among patients with stage IV denovo colon cancer

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab

Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC)

Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver

Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM)

Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis

A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results

Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM)

Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer

Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective

CHFR methylation as an epigenetic marker for recurrence of colon cancer

Association of PTEN loss and local recurrence in stage II-III colon cancer

Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): A matched-pair analysis

Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks

Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer

Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer

Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses

Aktive Filter

Suchergebnisse filtern